Drug Approval | October 16, 2024
Shilpa Medicare’s CDMO customer gets fast-track designation for its investigational drug candidate
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
He will join in place of Anil Arora, current President- Formulations Operations who will be superannuating in November, 2024
Lyka has received the CDSCO approval for manufacturing and marketing of Pregabalin Gel 8% w/w
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The acquisition will strengthen the overall company’s position as leading global CRO services partner
he company will focus on production of any pharmaceutical and biotechnological products
USFDA completes PAI of Lupin’s biotech facility in Pune
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
